Bookmark and Share
vicriviroc (CID 3009355) - Compound BioActivity Data
.
BioActivity Outcomes:
Active(20)
 
 
Inactive(5)
 
 
Inconclusive(5)
 
 
Unspecified(94)
 
 
Top Targets:
Glutaminase(1)
 
 
HpcH HpaI(1)
 
 
Firefly Luc l..(1)
 
 
BioAssay Types:
Literature(114)
 
 
 
 
Confirmatory(5)
 
 
BioActivity Types:
EC50(11)
 
 
 
 
IC50(6)
 
 
Potency(5)
 
 
Ki(3)
 
 
 
Data download

Chemical Probe    Active    Inactive    Inconclusive    Unspecified   

Total Bioassays: 124    Data Row: 124   Total Pages: 3   Display: Page     
Sort: [Click the result table header to sort]
#SubstanceActivityBioAssayTargetLinks
OutcomeTypeValue [μM]
1
[SID103281592]
IC50 0.00023Antiviral activity against HIV-1 BaL infected in PHA-stimulated human PBMC cells assessed as viral p24 core protein level after 7 days by ELISA [AID581321, Type: other]
View
2
[SID103281592]
EC50 0.00037Antiviral activity against HIV1 JRCSF infected in human PBMC assessed as inhibition of viral p24 antigen production after 7 to 10 days by ELISA [AID559939, Type: Literature]
View
3
[SID103281592]
IC50 0.00045Binding affinity to CCR5 [AID707904, Type: Literature]
View
4
[SID103281592]
IC50 0.00046Compound was tested for inhibiting the entry of replication defective HIV-1 (YU-2) in to U-80 cells [AID213881, Type: Literature]
View
5
[SID103281592]
IC50 0.00056Antiviral activity against HIV-1 ADA infected in PHA-stimulated human PBMC cells assessed as viral p24 core protein level after 7 days by ELISA [AID581320, Type: other]
View
6
[SID103281592]
EC50 0.0012Antiviral activity against HIV1 R5 infected in human PBMC assessed as inhibition of viral p24 antigen production after 7 to 10 days by ELISA [AID559940, Type: Literature]
View
7
[SID103281592]
IC50 0.0012Antagonist activity at CCR5 in IL-10 stimulated human PBMC cells assessed as MIP-1beta induced chemotaxis [AID581319, Type: other]C-C chemokine receptor type 5 [gi:1705896]
View
8
[SID103281592]
EC50 0.0014Antiviral activity against R5 tropic HIV1 JR-CSF in PM1/CCR5 cells assessed as protection from virus-induced cytopathogenicity measuring capsid p24 level after 5 days by ELISA [AID644281, Type: Literature]
View
9
[SID103281592]
Ki 0.0025Antagonistic activity against C-C chemokine receptor type 5 [AID42503, Type: Literature]
View
10
[SID103281592]
IC50 0.003Displacement of [125I]MIP-1beta from CCR5 in IL-10-stimulated human monocytes [AID581318, Type: other]C-C chemokine receptor type 5 [gi:1705896]
View
11
[SID103281592]
EC50 0.026Antiviral activity against R5 tropic HIV1 NL(AD8) in PM1/CCR5 cells assessed as protection from virus-induced cytopathogenicity after 5 days by MTT assay [AID644280, Type: Literature]
View
12
[SID103281592]
EC50 0.55Antiviral activity against R5-tropic HIV1 NL(AD8) infected in human PM1 cells expressing CCR5 assessed as protection from virus-induced cytopathogenicity [AID662536, Type: Literature]
View
13
[SID103281592]
Compound was tested for the inhibition of HIV-1 301657 clinical isolate in PBMC cultures [AID155469, Type: Literature]
View
14
[SID103281592]
Compound was tested for the inhibition of HIV-1 ADA-M clinical isolate in PBMC cultures [AID155470, Type: Literature]
View
15
[SID103281592]
Compound was tested for the inhibition of HIV-1 JV1083 clinical isolate in PBMC cultures [AID155471, Type: Literature]
View
16
[SID103281592]
Compound was tested for the inhibition of HIV-1 JrFL clinical isolate in PBMC cultures [AID155472, Type: Literature]
View
17
[SID103281592]
Compound was tested for the inhibition of HIV-1 RU 570 clinical isolate in PBMC cultures [AID155473, Type: Literature]
View
18
[SID103281592]
Antiviral activity against maraviroc-resistant HIV1 isolate CC185 at 100 times IC90 concentration [AID554061, Type: Literature]
View
19
[SID103281592]
Antiviral activity against maraviroc-resistant HIV1 isolate CC185 at 10 times IC90 concentration [AID554062, Type: Literature]
View
20
[SID103281592]
Antiviral activity against maraviroc-resistant HIV1 isolate CC185 at IC90 concentration [AID554063, Type: Literature]
View
21
[SID103281592]
EC50 1Antiviral activity against HIV1 NL4-3 infected in human PBMC assessed as inhibition of viral p24 antigen production after 7 to 10 days by ELISA [AID559935, Type: Literature]
View
22
[SID103281592]
EC50 1Antiviral activity against HIV1 X4 infected in human PBMC assessed as inhibition of viral p24 antigen production after 7 to 10 days by ELISA [AID559936, Type: Literature]
View
23
[SID103281592]
EC50 1Antiviral activity against HIV1 89.6 infected in human PBMC assessed as inhibition of viral p24 antigen production after 7 to 10 days by ELISA [AID559937, Type: Literature]
View
24
[SID103281592]
Ki 10Antagonistic activity against muscarinic M1 receptor [AID141165, Type: Literature]
View
25
[SID103281592]
Ki 10Antagonistic activity against Muscarinic acetylcholine receptor M2 [AID142512, Type: Literature]
View
26
[SID103281592]
Half life in human in repeated dosing regimen [AID581363, Type: other]
View
27
[SID103281592]
Lipophilicity, log P of the compound [AID707908, Type: Literature]
View
28
[SID103281592]
Cmax 24 hr after 2 mg/kg oral administration in monkeys [AID7321, Type: Literature]
View
29
[SID103281592]
Half-life 24 hr after 2 mg/kg iv administration in monkeys [AID7555, Type: Literature]
View
30
[SID103281592]
Area under curve value 24 hr after 2 mg/kg iv administration in monkeys [AID10237, Type: Literature]
View
31
[SID103281592]
Area under curve value 24 hr after 2 mg/kg oral administration in monkeys [AID10238, Type: Literature]
View
32
[SID103281592]
Bioavailability in monkey (dose 2 mg/kg) [AID10247, Type: Literature]
View
33
[SID103281592]
Half-life 24 hr after 10 mg/kg iv administration in rats [AID10465, Type: Literature]
View
34
[SID103281592]
Cmax 24 hr after 10 mg/kg oral administration in rats [AID11403, Type: Literature]
View
35
[SID103281592]
Area under curve value 24 hr after 10 mg/kg iv administration in rats [AID12727, Type: Literature]
View
36
[SID103281592]
Area under curve value 24 hr after 10 mg/kg oral administration in rats [AID12728, Type: Literature]
View
37
[SID103281592]
Area under curve value 6 hr after po administration in rat [AID12731, Type: Literature]
View
38
[SID103281592]
Bioavailability after administration of 10 mg/kg in rats [AID13139, Type: Literature]
View
39
[SID103281592]
Cardiotoxicity in healthy human assessed as change in corrected QT interval at 30 mg/kg, po after 10 days by ECG [AID518040, Type: Literature]
View
40
[SID103281592]
Cmax in healthy human at 150 mg/kg, po after 10 days [AID518043, Type: Literature]
View
41
[SID103281592]
Cmin in healthy human at 150 mg/kg, po after 10 days [AID518044, Type: Literature]
View
42
[SID103281592]
Tmax in healthy human at 150 mg/kg, po after 10 days [AID518045, Type: Literature]
View
43
[SID103281592]
AUC (0 to 24 hrs) in healthy human at 150 mg/kg, po after 10 days [AID518046, Type: Literature]
View
44
[SID103281592]
Cmax in healthy human at 30 mg/kg, po after 10 days [AID518047, Type: Literature]
View
45
[SID103281592]
Cmin in healthy human at 30 mg/kg, po after 10 days [AID518048, Type: Literature]
View
46
[SID103281592]
Tmax in healthy human at 30 mg/kg, po after 10 days [AID518049, Type: Literature]
View
47
[SID103281592]
AUC (0 to 24 hrs) in healthy human at 30 mg/kg, po after 10 days [AID518050, Type: Literature]
View
48
[SID103281592]
Toxicity in healthy human assessed as fatigue at 200 mg/kg, po administered as single dose [AID518061, Type: Literature]
View
49
[SID103281592]
Toxicity in healthy human assessed as headache at 200 mg/kg, po administered as single dose [AID518062, Type: Literature]
View
50
[SID103281592]
Toxicity in healthy human assessed as pollakiuria at 200 mg/kg, po administered as single dose [AID518063, Type: Literature]
View